Match!

Release of doxorubicin from its liposomal coating via high intensity ultrasound

Published on Sep 5, 2019in Molecular and Clinical Oncology
· DOI :10.3892/mco.2019.1917
Agata Mikolajczyk2
Estimated H-index: 2
(Wroclaw University of Environmental and Life Sciences),
Veria Khosrawipour6
Estimated H-index: 6
+ 4 AuthorsTanja Khosrawipour2
Estimated H-index: 2
(UCI: University of California, Irvine)
Abstract
The present ex vivo study was performed to analyze the impact of high intensity ultrasound (HIUS) on penetration depth and particle stability of liposomal doxorubicin (LD) on the peritoneal surface. Fresh post mortem swine peritoneum was cut into proportional sections and subjected to a previously established ex vivo model of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Samples were treated with 50 ml NaCl (0.9%) containing 3 mg LD via PIPAC or lavage. In both groups, half of the samples received additional HIUS treatment. Samples treated via PIPAC were covered with a 30-mm-thick abdominal muscle wall tissue, fatty tissue and skin, followed by transcutaneous HIUS. Samples administered with LD via lavage received close-range contact HIUS. Doxorubicin tissue penetration was measured using fluorescence microscopy on frozen sections. Liposomal integrity on peritoneal surfaces was measured via electron microscopy (EM). Mean penetration rates of doxorubicin were significantly higher with HIUS in combination with PIPAC or lavage compared with PIPAC alone (P<0.001) or lavage alone (P<0.00001). LD was not detected on the peritoneal surface via EM analysis in either group following HIUS. The present data suggested that HIUS may be a feasible application that can facilitate the release of doxorubicin from its liposomal envelope. HIUS was effective in both close-range, in contact with the samples, and through the abdominal wall. The present approach may be used in the future for both endoscopic and open lavage of the peritoneal cavity with LD in intraperitoneal chemotherapeutic applications such as hyperthermic intraperitoneal chemotherapy or PIPAC.
  • References (0)
  • Citations (2)
📖 Papers frequently viewed together
18 Citations
18 Citations
7 Authors (Chi-Mou Liu, ..., Te-Wei Lee)
5 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References0
Newest
Cited By2
Newest
#1Justyna Schubert (Wroclaw University of Environmental and Life Sciences)H-Index: 3
#2Tanja KhosrawipourH-Index: 2
Last. Veria Khosrawipour (UCI: University of California, Irvine)H-Index: 6
view all 8 authors...
Source
#1Giorgi Nadiradze (University of Tübingen)H-Index: 1
#1G. NadiradzeH-Index: 1
Last. Marc A. ReymondH-Index: 29
view all 7 authors...
Theoretical considerations as well as comprehensive preclinical and clinical data suggest that optimizing physical parameters of intraperitoneal drug delivery might help to circumvent initial or acquired resistance of peritoneal metastasis (PM) to chemotherapy. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel minimally invasive drug delivery system systematically addressing the current limitations of intraperitoneal chemotherapy. The rationale behind PIPAC is: 1) optimizing ho...
Source